Balaji Prasad
Stock Analyst at Barclays
(2.42)
# 2,314
Out of 4,826 analysts
147
Total ratings
41.13%
Success rate
-0.77%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $11.93 | +109.56% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $7.56 | +45.50% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $25.72 | -6.69% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $8.59 | +4.77% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $118.21 | +69.19% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $9.63 | +97.30% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $48.02 | +24.95% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $158.06 | +54.37% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $8.72 | +175.23% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $19.49 | +12.88% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $475.07 | +9.46% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $16.39 | +58.63% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $106.35 | +50.45% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $13.87 | +22.57% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $8.32 | +116.35% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $2.80 | +257.14% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.02 | +586.27% | 7 | Oct 23, 2023 | |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $11.93
Upside: +109.56%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $7.56
Upside: +45.50%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $25.72
Upside: -6.69%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $8.59
Upside: +4.77%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $118.21
Upside: +69.19%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $9.63
Upside: +97.30%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $48.02
Upside: +24.95%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $158.06
Upside: +54.37%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $8.72
Upside: +175.23%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $19.49
Upside: +12.88%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $475.07
Upside: +9.46%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $16.39
Upside: +58.63%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $106.35
Upside: +50.45%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $13.87
Upside: +22.57%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $8.32
Upside: +116.35%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $2.80
Upside: +257.14%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.02
Upside: +586.27%